Daniel Serrano
Research Subjects
Daniel Serrano has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Michael L. Reed
Vedanta Research Chapel Hill NC USA
3 shared publicationsRichard B. Lipton
Albert Einstein College of Medicine Bronx NY USA
3 shared publicationsAubrey N. Manack
Allergan Inc. Irvine CA USA
2 shared publicationsDawn C. Buse
Albert Einstein College of Medicine Bronx NY USA
2 shared publicationsCedric M. Cunanan
Allergan Inc. Irvine CA USA
1 shared publicationDaisy S. Ng-Mak
1 shared publication
Latest Publications
- 24 May 2013
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 53 (9) , 1415-1429
Effects of Switching Acute Treatment on Disability in Migraine Patients Using Triptans
Objective: To assess the influence of switching acute treatment on headache‐related disability in a population sample of individuals with migraine using acute triptan therapy. Background: Acute treatments for migraine are often modified in clinical practice. The effect of changes in treatment from one triptan to another or from a triptan to another medication class has rarely been studied. Methods: Patterns of acute treatment for migraine were monitored from 1 year to the next in the A merican M igraine P revalence and P revention (AMPP) Study for the following couplets (2005‐2006, 2006‐2007, 2007‐2008, and 2008‐2009). Changes in medication regimens were classified as follows: (1) switch within the triptan class; (2) switch to combination analgesics containing opioids or barbiturates; (3) switch to non‐steroidal anti‐inflammatory drug ( NSAID ) agents; (4) maintaining current therapy (consistent use, “control”). We assessed change in migraine disability assessment scale score from the first to the second year of a couplet contrasting those with consistent use with those who changed acute treatment. Each individual contributed only 1 couplet to the analysis. Persons who added an acute treatment are considered in a separate manuscript. We modeled change in migraine disability assessment scale score as a function of change in medication regimen with consistent users as the control group. Results: We identified 81 individuals who switched to another triptan, with a referent of 619 who remained consistent, 31 cases who switched to an opioid or barbiturate with a referent of 666 who remained consistent, and 20 cases who switched to an NSAID with a referent of 667 cases who remained consistent. In cell‐mean coded analyses of covariance (ANCOVA), switching from one triptan to another or switching from a triptan to an opioid/barbiturate was never associated with significant improvements in headache‐related disability compared with consistent treatment. Switching from a triptan to an NSAID was associated with significant increases in headache‐related disability among those with high‐frequency episodic/chronic migraine (HFEM/CM) compared with those with low‐frequency episodic migraine (LFEM) (interaction = 34.81, 95% confidence interval 10.61 to 59.00). The same was true comparing high‐frequency episodic/chronic migraine with those with moderate‐frequency episodic migraine (interaction = 48.73, 95% confidence interval 2.63 to 94.83). Conclusions: In this observational study, switching triptan regimens does not appear to be associated with improvements in headache‐related disability and in some cases is associated with increased headache‐related disability.
- 24 May 2013
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 53 (9) , 1415-1429
Effects of Switching Acute Treatment on Disability in Migraine Patients Using Triptans
Objective: To assess the influence of switching acute treatment on headache‐related disability in a population sample of individuals with migraine using acute triptan therapy. Background: Acute treatments for migraine are often modified in clinical practice. The effect of changes in treatment from one triptan to another or from a triptan to another medication class has rarely been studied. Methods: Patterns of acute treatment for migraine were monitored from 1 year to the next in the A merican M igraine P revalence and P revention (AMPP) Study for the following couplets (2005‐2006, 2006‐2007, 2007‐2008, and 2008‐2009). Changes in medication regimens were classified as follows: (1) switch within the triptan class; (2) switch to combination analgesics containing opioids or barbiturates; (3) switch to non‐steroidal anti‐inflammatory drug ( NSAID ) agents; (4) maintaining current therapy (consistent use, “control”). We assessed change in migraine disability assessment scale score from the first to the second year of a couplet contrasting those with consistent use with those who changed acute treatment. Each individual contributed only 1 couplet to the analysis. Persons who added an acute treatment are considered in a separate manuscript. We modeled change in migraine disability assessment scale score as a function of change in medication regimen with consistent users as the control group. Results: We identified 81 individuals who switched to another triptan, with a referent of 619 who remained consistent, 31 cases who switched to an opioid or barbiturate with a referent of 666 who remained consistent, and 20 cases who switched to an NSAID with a referent of 667 cases who remained consistent. In cell‐mean coded analyses of covariance (ANCOVA), switching from one triptan to another or switching from a triptan to an opioid/barbiturate was never associated with significant improvements in headache‐related disability compared with consistent treatment. Switching from a triptan to an NSAID was associated with significant increases in headache‐related disability among those with high‐frequency episodic/chronic migraine (HFEM/CM) compared with those with low‐frequency episodic migraine (LFEM) (interaction = 34.81, 95% confidence interval 10.61 to 59.00). The same was true comparing high‐frequency episodic/chronic migraine with those with moderate‐frequency episodic migraine (interaction = 48.73, 95% confidence interval 2.63 to 94.83). Conclusions: In this observational study, switching triptan regimens does not appear to be associated with improvements in headache‐related disability and in some cases is associated with increased headache‐related disability.
- 1 January 2013
- Published by Elsevier in Value in Health
- Vol. 16 (1) , 31-38
Cost and Predictors of Lost Productive Time in Chronic Migraine and Episodic Migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study
- 1 January 2013
- Published by Elsevier in Value in Health
- Vol. 16 (1) , 31-38
Cost and Predictors of Lost Productive Time in Chronic Migraine and Episodic Migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study